{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T16:08:44Z","timestamp":1790352524732,"version":"4.1.0"},"reference-count":71,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002224","name":"Melanoma Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002224","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001368","name":"V Foundation for Cancer Research","doi-asserted-by":"publisher","award":["5P30CA016042-48"],"award-info":[{"award-number":["5P30CA016042-48"]}],"id":[{"id":"10.13039\/100001368","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005190","name":"Melanoma Research Alliance","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005190","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["2R01CA176111-11"],"award-info":[{"award-number":["2R01CA176111-11"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1P01CA168585"],"award-info":[{"award-number":["1P01CA168585"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U54 CA274509"],"award-info":[{"award-number":["U54 CA274509"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA282198"],"award-info":[{"award-number":["R01CA282198"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5P30CA016042-48"],"award-info":[{"award-number":["5P30CA016042-48"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007186","name":"Jonsson Comprehensive Cancer Center, University of California, Los Angeles","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007186","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019319","name":"Ressler Family Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007185","name":"University of California, Los Angeles","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007185","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunity"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.immuni.2025.10.001","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T15:50:44Z","timestamp":1761925844000},"page":"2864-2877.e9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Genomic copy-number variants drive apoptotic evasion underlying acquired resistance to immune checkpoint inhibitors"],"prefix":"10.1016","volume":"58","author":[{"given":"Mingming","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyue","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhentao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirley H.","family":"Lomeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashanthi","family":"Dharanipragada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gatien","family":"Moriceau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Damoiseaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark C.","family":"Kelley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos N.","family":"Prieto-Granada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Giubellino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Nosrati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Kashani-Sabet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin B.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas B.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sixue","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5337-5004","authenticated-orcid":false,"given":"Roger S.","family":"Lo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.immuni.2025.10.001_bib1","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/s41577-023-00867-9","article-title":"Insights from a 30-year journey: function, regulation and therapeutic modulation of PD1","volume":"23","author":"Chamoto","year":"2023","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.immuni.2025.10.001_bib2","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.immuni.2025.10.001_bib3","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.cell.2015.03.030","article-title":"Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential","volume":"161","author":"Sharma","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2025.10.001_bib4","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The future of immune checkpoint therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.immuni.2025.10.001_bib5","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nrc.2016.36","article-title":"Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy","volume":"16","author":"Topalian","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.immuni.2025.10.001_bib6","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.ccell.2020.03.017","article-title":"Acquired Resistance to Immune Checkpoint Inhibitors","volume":"37","author":"Schoenfeld","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.immuni.2025.10.001_bib7","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1158\/2159-8290.CD-15-0283","article-title":"Loss of PTEN promotes resistance to T cell-mediated immunotherapy","volume":"6","author":"Peng","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.immuni.2025.10.001_bib8","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nature14404","article-title":"Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity","volume":"523","author":"Spranger","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2025.10.001_bib9","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/j.cell.2016.11.022","article-title":"Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade","volume":"167","author":"Benci","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2025.10.001_bib10","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1158\/2159-8290.CD-16-1223","article-title":"Primary Resistance to PD-1 Blockade Mediated by JAK1\/2 Mutations","volume":"7","author":"Shin","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.immuni.2025.10.001_bib11","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cell.2016.02.065","article-title":"Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma","volume":"165","author":"Hugo","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2025.10.001_bib12","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","article-title":"Genetic basis for clinical response to CTLA-4 blockade in melanoma","volume":"371","author":"Snyder","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.immuni.2025.10.001_bib13","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/s41591-023-02304-9","article-title":"Multi-organ landscape of therapy-resistant melanoma","volume":"29","author":"Liu","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.immuni.2025.10.001_bib14","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2025.10.001_bib15","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.immuni.2025.10.001_bib16","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ccell.2023.12.013","article-title":"Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer","volume":"42","author":"Memon","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.immuni.2025.10.001_bib17","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1158\/2159-8290.CD-22-0787","article-title":"Blocking Genomic Instability Prevents Acquired Resistance to MAPK Inhibitor Therapy in Melanoma","volume":"13","author":"Dharanipragada","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.immuni.2025.10.001_bib18","doi-asserted-by":"crossref","first-page":"6055","DOI":"10.1016\/j.cell.2024.08.001","article-title":"The Fanconi anemia pathway induces chromothripsis and ecDNA-driven cancer drug resistance","volume":"187","author":"Engel","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2025.10.001_bib19","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/nrg2593","article-title":"Mechanisms of change in gene copy number","volume":"10","author":"Hastings","year":"2009","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.immuni.2025.10.001_bib20","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.ccell.2022.12.009","article-title":"Base editing screens map mutations affecting interferon-gamma signaling in cancer","volume":"41","author":"Coelho","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.immuni.2025.10.001_bib21","article-title":"In vivo CRISPR screens reveal Serpinb9 and Adam2 as regulators of immune therapy response in lung cancer","volume":"14","author":"Dervovic","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.immuni.2025.10.001_bib22","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1038\/s41590-022-01315-x","article-title":"In vivo CRISPR screens reveal the landscape of immune evasion pathways across cancer","volume":"23","author":"Dubrot","year":"2022","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.immuni.2025.10.001_bib23","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.immuni.2021.01.001","article-title":"In vivo screens using a selective CRISPR antigen removal lentiviral vector system reveal immune dependencies in renal cell carcinoma","volume":"54","author":"Dubrot","year":"2021","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2025.10.001_bib24","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/s41588-021-00779-1","article-title":"Multimodal pooled Perturb-CITE-seq screens in patient models define mechanisms of cancer immune evasion","volume":"53","author":"Frangieh","year":"2021","journal-title":"Nat. Genet."},{"key":"10.1016\/j.immuni.2025.10.001_bib25","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/s41586-021-03520-4","article-title":"Epigenetic silencing by SETDB1 suppresses tumour intrinsic immunogenicity","volume":"595","author":"Griffin","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2025.10.001_bib26","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.84314","article-title":"Complementary CRISPR screen highlights the contrasting role of membrane-bound and soluble ICAM-1 in regulating antigen-specific tumor cell killing by cytotoxic T cells","volume":"12","author":"Herzfeldt","year":"2023","journal-title":"eLife"},{"key":"10.1016\/j.immuni.2025.10.001_bib27","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001819","article-title":"Integrating genome-wide CRISPR immune screen with multi-omic clinical data reveals distinct classes of tumor intrinsic immune regulators","volume":"9","author":"Hou","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.immuni.2025.10.001_bib28","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-29205-8","article-title":"CRISPR activation screen identifies BCL-2 proteins and B3GNT2 as drivers of cancer resistance to T cell-mediated cytotoxicity","volume":"13","author":"Joung","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.immuni.2025.10.001_bib29","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aar3451","article-title":"Tumor immune evasion arises through loss of TNF sensitivity","volume":"3","author":"Kearney","year":"2018","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.immuni.2025.10.001_bib30","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/s41586-020-2746-2","article-title":"Functional genomic landscape of cancer-intrinsic evasion of killing by T cells","volume":"586","author":"Lawson","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2025.10.001_bib31","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1158\/2159-8290.CD-19-0780","article-title":"In Vivo Epigenetic CRISPR Screen Identifies Asf1a as an Immunotherapeutic Target in Kras-Mutant Lung Adenocarcinoma","volume":"10","author":"Li","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.immuni.2025.10.001_bib32","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nature23270","article-title":"In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target","volume":"547","author":"Manguso","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2025.10.001_bib33","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1126\/science.aao1710","article-title":"A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing","volume":"359","author":"Pan","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.immuni.2025.10.001_bib34","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nature23477","article-title":"Identification of essential genes for cancer immunotherapy","volume":"548","author":"Patel","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2025.10.001_bib35","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1158\/2159-8290.CD-20-0756","article-title":"A Critical Role for Fas-Mediated Off-Target Tumor Killing in T-cell Immunotherapy","volume":"11","author":"Upadhyay","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.immuni.2025.10.001_bib36","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.cell.2019.06.014","article-title":"Augmenting Immunotherapy Impact by Lowering Tumor TNF Cytotoxicity Threshold","volume":"178","author":"Vredevoogd","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2025.10.001_bib37","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1158\/2159-8290.CD-19-1448","article-title":"CRISPR-GEMM Pooled Mutagenic Screening Identifies KMT2D as a Major Modulator of Immune Checkpoint Blockade","volume":"10","author":"Wang","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.immuni.2025.10.001_bib38","doi-asserted-by":"crossref","first-page":"5357","DOI":"10.1016\/j.cell.2021.09.006","article-title":"In vivo CRISPR screens identify the E3 ligase Cop1 as a modulator of macrophage infiltration and cancer immunotherapy target","volume":"184","author":"Wang","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2025.10.001_bib39","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-14290-4","article-title":"Tumor heterogeneity and clonal cooperation influence the immune selection of IFN-gamma-signaling mutant cancer cells","volume":"11","author":"Williams","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.immuni.2025.10.001_bib40","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/j.cmet.2023.07.001","article-title":"Tumor aerobic glycolysis confers immune evasion through modulating sensitivity to T cell-mediated bystander killing via TNF-\u03b1","volume":"35","author":"Wu","year":"2023","journal-title":"Cell Metab."},{"key":"10.1016\/j.immuni.2025.10.001_bib41","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abb9561","article-title":"Autophagy protects tumors from T cell-mediated cytotoxicity via inhibition of TNFalpha-induced apoptosis","volume":"5","author":"Young","year":"2020","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.immuni.2025.10.001_bib42","article-title":"RNF31 inhibition sensitizes tumors to bystander killing by innate and adaptive immune cells","volume":"3","author":"Zhang","year":"2022","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.immuni.2025.10.001_bib43","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1158\/2159-8290.CD-20-0873","article-title":"Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity","volume":"11","author":"Hong","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.immuni.2025.10.001_bib44","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.cell.2015.07.061","article-title":"Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance","volume":"162","author":"Hugo","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2025.10.001_bib45","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.ccell.2014.11.018","article-title":"Tunable-Combinatorial Mechanisms of Acquired Resistance Limit the Efficacy of BRAF\/MEK Cotargeting but Result in Melanoma Drug Addiction","volume":"27","author":"Moriceau","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.immuni.2025.10.001_bib46","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1158\/2159-8290.CD-13-0642","article-title":"Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy","volume":"4","author":"Shi","year":"2014","journal-title":"Cancer Discov."},{"key":"10.1016\/j.immuni.2025.10.001_bib47","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms1727","article-title":"Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance","volume":"3","author":"Shi","year":"2012","journal-title":"Nat. Commun."},{"key":"10.1016\/j.immuni.2025.10.001_bib48","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/s41586-022-04738-6","article-title":"Signatures of copy number alterations in human cancer","volume":"606","author":"Steele","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2025.10.001_bib49","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.celrep.2017.04.031","article-title":"Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression","volume":"19","author":"Garcia-Diaz","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.immuni.2025.10.001_bib50","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.cell.2019.07.009","article-title":"T-Scan: A Genome-wide Method for the Systematic Discovery of T Cell Epitopes","volume":"178","author":"Kula","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2025.10.001_bib51","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-28741-7","article-title":"Co-targeting of BAX and BCL-XL proteins broadly overcomes resistance to apoptosis in cancer","volume":"13","author":"Lopez","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.immuni.2025.10.001_bib52","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.ccell.2021.07.023","article-title":"Anti-PD-1\/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy","volume":"39","author":"Wang","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.immuni.2025.10.001_bib53","doi-asserted-by":"crossref","DOI":"10.1186\/s13059-022-02794-9","article-title":"MEDICC2: whole-genome doubling aware copy-number phylogenies for cancer evolution","volume":"23","author":"Kaufmann","year":"2022","journal-title":"Genome Biol."},{"key":"10.1016\/j.immuni.2025.10.001_bib54","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.immuni.2017.02.001","article-title":"Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma","volume":"46","author":"George","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2025.10.001_bib55","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/nature08822","article-title":"The landscape of somatic copy-number alteration across human cancers","volume":"463","author":"Beroukhim","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2025.10.001_bib56","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1038\/nature08768","article-title":"Signatures of mutation and selection in the cancer genome","volume":"463","author":"Bignell","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2025.10.001_bib57","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1126\/science.1219580","article-title":"Recurrent hemizygous deletions in cancers may optimize proliferative potential","volume":"337","author":"Solimini","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.immuni.2025.10.001_bib58","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.trecan.2022.12.003","article-title":"Resisting T cell attack: tumor-cell-intrinsic defense and reparation mechanisms","volume":"9","author":"McKenzie","year":"2023","journal-title":"Trends Cancer"},{"key":"10.1016\/j.immuni.2025.10.001_bib59","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0065-2776(08)60911-6","article-title":"Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance","volume":"74","author":"Marincola","year":"2000","journal-title":"Adv. Immunol."},{"key":"10.1016\/j.immuni.2025.10.001_bib60","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.trecan.2022.07.007","article-title":"T cell-mediated additive cytotoxicity - death by multiple bullets","volume":"8","author":"Weigelin","year":"2022","journal-title":"Trends Cancer"},{"key":"10.1016\/j.immuni.2025.10.001_bib61","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aah3560","article-title":"Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance","volume":"9","author":"Roh","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.immuni.2025.10.001_bib62","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nature22393","article-title":"Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin","volume":"547","author":"Wang","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2025.10.001_bib63","doi-asserted-by":"crossref","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","article-title":"Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria","volume":"15","author":"Wolchok","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.immuni.2025.10.001_bib64","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.immuni.2025.10.001_bib65","doi-asserted-by":"crossref","first-page":"3968","DOI":"10.1016\/j.cell.2023.07.024","article-title":"Archival single-cell genomics reveals persistent subclones during DCIS progression","volume":"186","author":"Wang","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2025.10.001_bib66","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/nmeth.1923","article-title":"Fast gapped-read alignment with Bowtie 2","volume":"9","author":"Langmead","year":"2012","journal-title":"Nat. Methods"},{"key":"10.1016\/j.immuni.2025.10.001_bib67","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1093\/bioinformatics\/btv098","article-title":"Sambamba: fast processing of NGS alignment formats","volume":"31","author":"Tarasov","year":"2015","journal-title":"Bioinformatics"},{"key":"10.1016\/j.immuni.2025.10.001_bib68","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/biostatistics\/kxh008","article-title":"Circular binary segmentation for the analysis of array-based DNA copy number data","volume":"5","author":"Olshen","year":"2004","journal-title":"Biostatistics"},{"key":"10.1016\/j.immuni.2025.10.001_bib69","doi-asserted-by":"crossref","DOI":"10.1002\/cpbi.96","article-title":"Using ggtree to Visualize Data on Tree-Like Structures","volume":"69","author":"Yu","year":"2020","journal-title":"Curr. Protoc. Bioinformatics"},{"key":"10.1016\/j.immuni.2025.10.001_bib70","article-title":"Metascape provides a biologist-oriented resource for the analysis of systems-level datasets","volume":"10","author":"Zhou","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.immuni.2025.10.001_bib71","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.ccell.2025.01.009","article-title":"Genomic mediators of acquired resistance to immunotherapy in metastatic melanoma","volume":"43","author":"Schiantarelli","year":"2025","journal-title":"Cancer Cell"}],"container-title":["Immunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1074761325004315?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1074761325004315?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T12:13:07Z","timestamp":1778587987000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1074761325004315"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":71,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S1074761325004315"],"URL":"https:\/\/doi.org\/10.1016\/j.immuni.2025.10.001","relation":{},"ISSN":["1074-7613"],"issn-type":[{"value":"1074-7613","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genomic copy-number variants drive apoptotic evasion underlying acquired resistance to immune checkpoint inhibitors","name":"articletitle","label":"Article Title"},{"value":"Immunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.immuni.2025.10.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}